BioSpace News Archive

The 87th China International Medical Equipment Fair attracted industry elites from more than 20 countries and regions around the world under the theme of “Innovative Technology · Smart Future”.

Sunshine Biopharma Inc. closed its previously announced private placement pursuant to a securities purchase agreement with a single healthcare-focused institutional investor for gross proceeds of approximately $5 million, before deducting fees to the placement agent and other offering expenses payable by the Company.

Medtronic plc (NYSE: MDT) today announced its AccuRhythm™ AI algorithm technology is the winner of the 7th annual MedTech Breakthrough Awards program as the “Best New Monitoring Solution.”

ScreenPro Security Inc. (CSE: SCRN) (OTCQB: SCRSF) (“ScreenPro” or the “Company”) is pleased to announce that it will change its name to “Justera Health Ltd.”

Fresenius Kabi announced today that the Centers for Medicare and Medicaid Services (CMS) issued a permanent product-specific Q-code for Stimufend® (pegfilgrastim-fpgk).

Akero Therapeutics, Inc. announced the pricing of an underwritten offering of 5,238,500 shares of its common stock at a price of $42.00 per share, before deducting underwriting discounts and commissions, for total gross proceeds of approximately $220.0 million.

HiST Pharma through its wholly-owned Psoriasis Research Institute of Guangzhou (PRIG) announces today that the U.S. Food and Drug Administration (FDA) has approved its Investigational New Drug (IND) TC Cream to launch a U.S.-based multicenter Phase III clinical study to treat patients with psoriasis vulgaris, following a previously completed Phase IIb trial (NCT03372811).

Takeda (TSE: 4502/NYSE:TAK) today announced that the U.S. Food and Drug Administration (FDA) has accepted Takeda’s Biologics License Application (BLA) for TAK-755, an enzyme replacement therapy for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP), an ADAMTS13 deficiency disorder.

Akari Therapeutics, Plc today announced that the company will participate in Alliance Global Partners’ Virtual Healthcare Conference being held May 23-24, 2023.

Ocean Biomedical, Inc. announced that it has entered into a private placement pursuant to a securities purchase agreement with Alto Opportunity Master Fund, SPC – Segregated Master Portfolio B for the issuance and sale of a total anticipated $25 million facility of Senior Secured Convertible Promissory Notes.